Form 4: Repligen Corp Director Rohin Mhatre Reports Stock and Option Awards

Director Rohin Mhatre reports the acquisition of restricted stock units and stock options in Repligen Corporation.

Summary

• On May 15, 2025, Rohin Mhatre, a director of Repligen Corporation, reported the acquisition of 973 restricted stock units (RSUs) and 1,800 stock options.
• The RSUs represent a contingent right to receive one share of Repligen Corporation's common stock each.
• The RSUs vest on the earlier of May 15, 2026, or the date of the next annual meeting of the company's shareholders.
• The stock options have an exercise price of $123.26 and expire on May 15, 2035.
• The stock options vest in full on the earlier of May 15, 2026, or the date of the next annual meeting of the company's shareholders.
• Following the reported transactions, Mhatre beneficially owns 4,019 shares of common stock and 1,800 stock options.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reports standard compensation practices. It's neither particularly positive nor negative from an investment perspective.

Positives

• The grant of RSUs and stock options to a director could be seen as an incentive to align their interests with those of the shareholders.

Future Outlook

The vesting of the RSUs and stock options is contingent upon future events, specifically the earlier of May 15, 2026, or the date of the next annual meeting of the company's shareholders, which has not yet been determined.

Industry Context

This is a routine disclosure related to executive compensation and is common in publicly traded companies. It reflects standard practices for incentivizing and retaining key personnel.

Comparison to Industry Standards

• Stock option and RSU grants are a common form of compensation for directors and executives in publicly traded companies, particularly in the biotech and pharmaceutical industries.
• Companies like Thermo Fisher Scientific, Danaher, and Sartorius also utilize similar equity-based compensation plans to align management interests with shareholder value.
• The vesting schedules and exercise prices are generally in line with industry norms, designed to incentivize long-term performance.

Stakeholder Impact

• The grant of stock options and restricted stock units could potentially align the director's interests more closely with those of the shareholders.
• Employees may view this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

Repligen, RGEN, Rohin Mhatre, Director, Stock Options, Restricted Stock Units, Form 4, Beneficial Ownership